According to the report published by Visiongain, the Attention Deficit Hyperactivity Disorder market is projected at USD 17.7 billion in 2020 and is predicted to be 6.4 percent CAGR over the 2020-2030 prediction. The industry is probable to be driven by product releases around the globe, acceptance of fresh drugs and enhanced research and development operations.
The worldwide expenditure on ADHD drugs shifted from use to expenditure by 2003 was US$ 2.4 billion, indicating a nine-fold rise since 1993. Expenditure rose rapidly from 1993 to 2000, but the annual growth pace rose steeper to 40.9 points after 2000. This acceleration was mainly motivated by the U.S. industry, where new drugs were accessible, mainly longer-acting formulations. The U.S. dominates worldwide expenditure on ADHD medicines, accounting for about 92-95 percent of annual expenditure, with a development pace of 22.6 percent per year. Other nations reported a development level of expenditure mildly faster than the United States— about 21.0 percent per year. A country-by-country analysis reveals that spending increases were much more pronounced in developed countries.
During the study period, the use of ADHD drugs improved by 274 times. Global quantity rose rapidly from 1993 to 2000 (13.2 percent per year); development accelerated to 16.8 percent per year from 2000 to 2003. Global business percentage in the U.S. decreased from 86.8% in 1993 to 83.1% in 2003. A more thorough assessment shows significant country-by-country variability. Low-use nations showed development levels as large as 46% per year, while moderate-use nations showed development levels of approximately 20% per year. The U.S. market share should proceed to drop if these levels persist.
Attention-deficit-hyperactivity disorder (ADHD) impacts more than 40 million individuals across main pharmaceutical industries, kids, adolescents and adults. Key objectives for both pediatric and adult ADHD therapy include managing the core characteristics of inattention and/or hyperactivity / impulsivity of the disorder and enhancing the general workings and standard of lives of clients. Psychostimulants are the predominant category of drugs approved for pediatric and adolescent ADHD, although there are no stimulant therapies that function as alternatives or later choices. However, shortcomings in current therapies constitute prospective regions for differentiating from rivals for evolving therapies. Additionally, adult ADHD identification and diagnosis continues to develop, especially in the United States, but this population remains under detection and under-treatment, depicting a significant market opportunity.
Why you should buy Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030: Forecasts and Analysis by Drug Type (Stimulant, Non-stimulant), By Demographic, By Distribution Channel (Hospital & Retail Pharmacy) and Geography, with Profiles of Leading Companies.
What is the future of the Attention Deficit Hyperactivity Disorder market? Visiongain’s comprehensive analysis contains highly quantitative content delivering solid conclusions benefiting your analysis and illustrates new opportunities and potential revenue streams helping you to remain competitive. This definitive report will benefit your decision making and help to direct your future business strategy.
We guarantee in this 171 page report you will receive the following key information –
– View Attention Deficit Hyperactivity Disorder market forecasts and analysis from 2020-2030 to keep you ahead of your competitors and ensure you exploit key business opportunities
– The report provides detailed sales projections of the market, the competitors, and the commercial drivers and restraints allowing you to more effectively compete in the market. In addition to market forecasts from 2020-2030, our new study shows current market data, original critical analysis, and revealing insight into commercial developments
– Attention Deficit Hyperactivity Disorder revenue forecast
– Attention Deficit Hyperactivity Disorder connections forecast
– Examine 122 tables, charts, and graphs.
– Let our analysts present you with a thorough assessment of the current and future Attention Deficit Hyperactivity Disorder market prospects.
– This analysis will achieve quicker, easier understanding. Also you will gain from our analyst’s industry expertise allowing you to demonstrate your authority on the Attention Deficit Hyperactivity Disorder sector
– Discover sales predictions for the key end use submarkets from 2020-2030
– What are the dynamics of the Attention Deficit Hyperactivity Disorder industry? Which submarkets will generate the most revenue? Use our forecasts and expert insight to grow your business and give you more industry influence. Find where you can gain and how your organisation can succeed. Avoid falling behind. Stay informed about the potential for each of these Attention Deficit Hyperactivity Disorder submarkets with individual forecasts and analysis from 2020-2030.
– Drug submarket forecast 2020-2030
– Drug Type submarket forecast 2020-2030
– Distribution Channel submarket forecast 2020-2030
– Learn about the market prospects for the leading Attention Deficit Hyperactivity Disorder market segments 2020-2030
– How will various value chain members perform over the forecast period? Discover where the highest revenue potential lies from 2020-2030, learning about how Attention Deficit Hyperactivity Disorder revenue trickles down through the various market segments. These forecasts will also reveal the competitive landscape. You will see what is happening, explaining the challenges, trends, competitors, and market opportunities. Our report reveals forecasts for the 3 leading segmentations as follows.
– Drug Revenue Forecast 2020-2030
– Bupropion Market Forecast, 2020-2030
– Clonidine Market Forecast, 2020-2030
– Guanfacine Market Forecast, 2020-2030
– Atomoxetine Market Forecast, 2020-2030
– Dexmethylphenidate Market Forecast, 2020-2030
– Lisdexamfetamine Market Forecast, 2020-2030
– Methylphenidate Market Forecast, 2020-2030
– Amphetamine Market Forecast, 2020-2030
– Other Drug Market Forecast, 2020-2030
– Drug Type Revenue Forecast 2020-2030
– Stimulant Market Forecast, 2020-2030
– Non-stimulant Market Forecast, 2020-2030
– Other Drug Type Market Forecast, 2020-2030
– Distribution Channel Revenue Forecast 2020-2030
– Hospital pharmacies Market Forecast, 2020-2030
– Specialty clinics Market Forecast, 2020-2030
– Retail pharmacies Market Forecast, 2020-2030
– Online pharmacies Market Forecast, 2020-2030
– Other Distribution Channel Market Forecast, 2020-2030
– Understand the prospects for the 4 regional and the leading 12 national Attention Deficit Hyperactivity Disorder markets – where will the highest revenues and opportunities occur?
– Learn about the market potential for Attention Deficit Hyperactivity Disorder companies in the developed and developing countries, from 2019 onwards. You will see where and how opportunities exist with revealing individual market forecasts and analysis from 2020-2030 for 12 leading national markets by revenue, as well as segmented regional forecasts
– North America Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– US Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Canada Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Mexico Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– North America Attention Deficit Hyperactivity Disorder by Drug revenue forecast 2020-2030
– North America Attention Deficit Hyperactivity Disorder by Drug Type revenue forecast 2020-2030
– North America Attention Deficit Hyperactivity Disorder by Distribution Channel revenue forecast 2020-2030
– Asia Pacific Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– China Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Japan Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– India Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Australia Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Rest of Asia Pacific Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Asia Pacific Attention Deficit Hyperactivity Disorder by Drug revenue forecast 2020-2030
– Asia Pacific Attention Deficit Hyperactivity Disorder by Drug Type revenue forecast 2020-2030
– Asia Pacific Attention Deficit Hyperactivity Disorder by Distribution Channel revenue forecast 2020-2030
– European Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Germany Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– UK Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– France Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Italy Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Spain Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Rest of Europe Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– European Attention Deficit Hyperactivity Disorder by Drug revenue forecast 2020-2030
– European Attention Deficit Hyperactivity Disorder by Drug Type revenue forecast 2020-2030
– European Attention Deficit Hyperactivity Disorder by Distribution Channel revenue forecast 2020-2030
– Rest of World Attention Deficit Hyperactivity Disorder revenue forecast 2020-2030
– Rest of World Attention Deficit Hyperactivity Disorder by Drug revenue forecast 2020-2030
– Rest of World Attention Deficit Hyperactivity Disorder by Drug Type revenue forecast 2020-2030
– Rest of World Attention Deficit Hyperactivity Disorder by Distribution Channel revenue forecast 2020-2030
– Explore the factors affecting Attention Deficit Hyperactivity Disorder product developers, and everyone within the value chain. Learn about the forces influencing market dynamics.
– Discover what the present and future outlook for business will be. Learn about the following business critical issues
– Research and development (R&D) strategy
– Technological issues and constraints.
– Competition from new product types
– Increasing specialisation by leading players
– Increasing industry consolidation.
– Advances in product quality
– Analysis of barriers to entry
– Identify who the leading companies are in the Attention Deficit Hyperactivity Disorder industry
– Our report reveals the technologies and companies which hold the greatest potential. In particular, exploring and analyzing the activities of these companies: See where the expected gains will be. View visiongain’s assessment of the prospects for established competitors, rising companies, and new market entrants. Our work explains that potential, helping you stay ahead. Gain a thorough understanding of the competitive landscape with profiles of 10 leading Attention Deficit Hyperactivity Disorder companies examining their positioning, capabilities, product portfolios, R&D activity, services, focus, strategies, M&A activity, and future outlook.
Leading Companies in the Global Attention Deficit Hyperactivity Disorder Market
Novartis AG
Eli Lily & Company
GI Dynamics
NEOS Therapeutics Inc.
Prude Pharma L.P.
Mallinckrodt
Shire
Lupin
Johnson & Johnson Services, LLC
Pfizer
Discover Information found nowhere else in this independent assessment of the Attention Deficit Hyperactivity Disorder market
The Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030: Forecasts and Analysis By Drug, By Drug Type, By Distribution Channel and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Attention Deficit Hyperactivity Disorder sector analysis. With the independent business intelligence found only in our work, you will discover where the prospects are for profit. In particular, our new research provides you with key strategic advantages: Our informed forecasts, independent and objective analysis, exclusive interviews and revealing company profiles will provide you with that necessary edge, allowing you to gain ground over your competitors.
With this report you are less likely to fall behind in knowledge or miss crucial business opportunities. You will save time and receive recognition for your market insight. See how you this report could benefit and enhance your research, analysis, company presentations and ultimately your individual business decisions and your company’s prospects.
What makes this report unique?
Visiongain’s research methodology involves an exclusive blend of primary and secondary sources providing informed analysis. This methodology allows insight into the key drivers and restraints behind market dynamics and competitive developments. The report therefore presents an ideal balance of qualitative analysis combined with extensive quantitative data including global, submarket and regional markets forecasts from 2020-2030
bForecasts and Analysis By Drug, By Drug Type, By Distribution Channel and and Geography, with Profiles of Leading Companies report can benefit you
Visiongain’s report is for anyone requiring analysis of the Attention Deficit Hyperactivity Disorder market. You will discover market forecasts, technological trends, predictions and expert opinion providing you with independent analysis derived from our extensive primary and secondary research. Only by purchasing this report will you receive this critical business intelligence revealing where revenue growth is likely and where the lucrative potential market prospects are. Don’t miss this key opportunity to gain a competitive advantage.
Avoid falling behind your competitors, overlooking critical business opportunities or losing industry influence. In our new report you will discover forecasts from 2020-2030 at the global, submarket, and national level. The report also assesses technologies, competitive forces and expected product pipeline developments. Read on to discover the prospects for the Attention Deficit Hyperactivity Disorder sector and find out what its future market prospects are.
If you buy our report today your knowledge will stay one step ahead of your competitors. Discover how our report could benefit your research, analyses and strategic decisions, saving you time. To gain an understanding of how to tap into the potential of this market and stay one step ahead of the competition you must order now our report the Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030: Forecasts and Analysis By Drug, By Drug Type, By Distribution Channel and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Attention Deficit Hyperactivity Disorder sector analysis. Avoid missing out – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Report Overview
1.1 Global Attention Deficit Hyperactivity Disorder Market Definition
1.2 Global Attention Deficit Hyperactivity Disorder Market Overview
1.3 Global Attention Deficit Hyperactivity Disorder Market Segmentation
1.4 Research Scope of Attention Deficit Hyperactivity Disorder in the Industry
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Methodology
1.8.1 Secondary Research
1.8.2 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Attention Deficit Hyperactivity Disorder Systems Market
2.1 Market Definition
2.2 Industry Structure
2.3 Industry Outlook
2.4 Current Status & Trends
2.4.1 Increasing awareness regarding ADHD among physicians and patients
2.4.2 Less availability of non-stimulants ADHD drugs
2.4.3 Underdiagnoses of ADHD
2.4.4 Increasing prevalence of ADHD
2.5 Product Penetration & growth prospect Analysis
2.5.1 Advanced manufacturing process innovation
3. Global Attention Deficit Hyperactivity Disorder Market Analysis
3.1 PEST Analysis of the Attention Deficit Hyperactivity Disorder Market
3.2 Expert Opinion
3.2.1 Primary Correspondents
3.3 Market Outlook
3.4 Drivers & Restraints
3.5 Dominant Region/Country
3.6 Market Scenario
3.7 Overall Growth Rate, Globally
3.8 SWOT Analysis of the Attention Deficit Hyperactivity Disorder Market
3.8.1 Strengths
3.8.2 Weaknesses
3.8.3 Opportunities
3.8.4 Threats
3.9 Porter’s Five Forces Analysis
3.9.1 Competitive Rivalry
3.9.1.1 Powerful Competitive Strategy
3.9.1.2 Firm Concentration Ratio
3.9.1.3 Degree Of Transparency
3.9.2 Supplier Power
3.9.2.1 Supplier Switching Costs Relative To Firm Switching Costs
3.9.2.2 Supplier Concentration To Firm Concentration Ratio
3.9.2.3 Degree Of Differentiation Of Inputs
3.9.3 Buyer Power
3.9.3.1 Degree Of Dependency Upon Existing Channels Of Distribution
3.9.3.2 Buyer Switching Costs Relative To Firm Switching Costs
3.9.3.3 Buyer Concentration To Firm Concentration Ratio
3.9.4 Threat Of Substitute
3.9.4.1 Buyer Propensity To Substitute
3.9.4.2 Relative Price Performance Of Substitute
3.9.4.3 Perceived Level Of Product Differentiation
3..9.5 Threat Of New Entrant
3.9.5.1 Economies Of Scale
3.9.5.2 Switching Costs Or Sunk Costs
3.9.5.3 Industry Profitability (Market CAGR)
4. Attention Deficit Hyperactivity Disorder: Global Market Analysis by Segments
4.1 Global Attention Deficit Hyperactivity Disorder Market Forecast, by Drug 2020-2030
4.1.1 Drug Overview
4.1.2 Bupropion Market Forecast, 2020-2030
4.1.3 Clonidine Market Forecast, 2020-2030
4.1.4 Guanfacine Market Forecast, 2020-2030
4.1.5 Atomoxetine Market Forecast, 2020-2030
4.1.6 Dexmethylphenidate Market Forecast, 2020-2030
4.1.7 Lisdexamfetamine Market Forecast, 2020-2030
4.1.7 Methylphenidate Market Forecast, 2020-2030
4.1.7 Amphetamine Market Forecast, 2020-2030
4.1.7 Other Drug Market Forecast, 2020-2030
4.2 Global Attention Deficit Hyperactivity Disorder Market Forecast, by Drug Type 2020-2030
4.2.1 Drug Type Overview
4.2.2 Stimulant Market Forecast, 2020-2030
4.2.3 Non-stimulant Market Forecast, 2020-2030
4.2.4 Other Drug Type Market Forecast, 2020-2030
4.3 Global Attention Deficit Hyperactivity Disorder Market Forecast, by Distribution Channel 2020-2030
4.3.1 Distribution Channel Overview
4.3.2 Hospital pharmacies Market Forecast, 2020-2030
4.3.3 Specialty clinics Market Forecast, 2020-2030
4.3.4 Retail pharmacies Market Forecast, 2020-2030
4.3.5 Online pharmacies Market Forecast, 2020-2030
4.3.6 Other Distribution Channel Market Forecast, 2020-2030
5. Leading Regions in Attention Deficit Hyperactivity Disorder Market 2020-2030
5.1 Regional Overview
5.1.1 North America
5.1.2 Europe
5.1.3 Asia Pacific
5.1.4 LAMEA
5.1.5 Leading Countries/ Regions
5.2 North America Attention Deficit Hyperactivity Disorder Market Forecast, 2020-2030
5.2.1 North America Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
5.2.2 North America Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030
5.2.3 North America Attention Deficit Hyperactivity Disorder Submarket, By Distribution Channel Forecast 2020-2030
5.2.4 North America Attention Deficit Hyperactivity Disorder Submarket, By Country Forecast 2020-2030
5.2.4.1 U.S. Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.2.4.2 Canada Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.2.4.3 Mexico Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3 Europe Attention Deficit Hyperactivity Disorder Market Forecast, 2020-2030
5.3.1 Europe Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
5.3.2 Europe Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030
5.3.3 Europe Attention Deficit Hyperactivity Disorder Submarket, By Distribution Channel Forecast 2020-2030
5.3.4 Europe Attention Deficit Hyperactivity Disorder Submarket, By Country Forecast 2020-2030
5.3.4.1 U.K. Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3.4.2 Germany Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3.4.3 France Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3.4.4 Italy Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3.4.5 Spain Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3.4.6 The Netherlands Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.3.4.7 Rest of Europe Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4 Asia-Pacific Attention Deficit Hyperactivity Disorder Market Forecast, 2020-2030
5.4.1 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
5.4.2 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030
5.4.3 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Distribution Channel Forecast 2020-2030
5.4.4 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Country Forecast 2020-2030
5.4.4.1 China Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4.4.2 India Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4.4.3 Japan Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4.4.4 Korea Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4.4.5 Indonesia Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4.4.6 Australia Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.4.4.7 Rest of Asia-Pacific Attention Deficit Hyperactivity Disorder Market, Forecast 2020-2030
5.5 Rest of World Attention Deficit Hyperactivity Disorder Market Forecast, 2020-2030
5.5.1 Rest of World Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
5.5.2 Rest of World Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030
5.5.3 Rest of World Attention Deficit Hyperactivity Disorder Submarket, By Distribution Channel Forecast 2020-2030
6. Leading Companies in The Attention Deficit Hyperactivity Disorder Market
6.1 Novartis AG
6.1.1 Novartis AG Overview
6.1.2 Analysis of Novartis AG Products and Services
6.1.3 Novartis AG Primary Market Competitors 2019
6.1.4 Novartis AG Key Developments
6.2 Eli Lily & Company
6.2.1 Eli Lily & Company Company Overview
6.2.2 Analysis of Eli Lily & Company Products and Services
6.2.3 Eli Lily & Company Primary Market Competitors 2019
6.2.4 Eli Lily & Company Key Developments
6.3 GI Dynamics
6.3.1 GI Dynamics Company Overview
6.3.2 Analysis of GI Dynamics Products and Services
6.3.3 GI Dynamics Primary Market Competitors 2019
6.3.4 GI Dynamics Key Developments
6.4 NEOS Therapeutics Inc.
6.4.1 NEOS Therapeutics Inc. Company Overview
6.4.2 Analysis of NEOS Therapeutics Inc. Products and Services
6.4.3 NEOS Therapeutics Inc. Primary Market Competitors 2019
6.4.4 NEOS Therapeutics Inc. Key Developments
6.5 Prude Pharma L.P.
6.5.1 Prude Pharma L.P. Company Overview
6.5.2 Analysis of Prude Pharma L.P. Products and Services
6.5.3 Prude Pharma L.P. Primary Market Competitors 2019
6.5.4 Prude Pharma L.P. Key Developments
6.6 Mallinckrodt
6.6.1 Mallinckrodt Company Overview
6.6.2 Analysis of Mallinckrodt Products and Services
6.6.3 Mallinckrodt Primary Market Competitors 2019
6.6.4 Mallinckrodt Key Developments
6.7 Shire
6.7.1 Shire Company Overview
6.7.2 Analysis of Shire Products and Services
6.7.3 Shire Primary Market Competitors 2019
6.7.4 Shire Key Developments
6.8 Lupin
6.8.1 Lupin Company Overview
6.8.2 Analysis of Lupin Products and Services
6.8.3 Lupin Primary Market Competitors 2019
6.8.4 Lupin Key Developments
6.9 Johnson & Johnson Services, LLC
6.9.1 Johnson & Johnson Services, LLC Company Overview
6.9.2 Analysis of Johnson & Johnson Services, LLC Products and Services
6.9.3 Johnson & Johnson Services, LLC Primary Market Competitors 2019
6.9.4 Johnson & Johnson Services, LLC Key Developments
6.10 Pfizer
6.10.1 Pfizer Company Overview
6.10.2 Analysis of Pfizer Products and Services
6.10.3 Pfizer Primary Market Competitors 2019
6.10.4 Pfizer Key Developments
7. Conclusions and Recommendations
7.1. Key Research Findings
7.2. Conclusion by Geography
7.3. Conclusion by Solution Type
7.4. Strategic Recommendations
8. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form
List of Figures
Figure 1.1 Global Attention Deficit Hyperactivity Disorder Market Segmentation
Figure 2.1 Attention Deficit Hyperactivity Disorder Value Chain Analysis
Figure 3.1 Attention Deficit Hyperactivity Disorder Supply-Demand Analysis
Figure 4.1 Global Attention Deficit Hyperactivity Disorder Forecast 2020-2030 ($billion, AGR %)
Figure 4.2 Global Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030
Figure 4.3 Global Attention Deficit Hyperactivity Disorder Submarket Forecast by 2020-2030 ($ billion)
Figure 4.4 Global Attention Deficit Hyperactivity Disorder Market By Drug Share Forecast 2019, 2025, 2029 (% Share)
Figure 4.19 Global Attention Deficit Hyperactivity Disorder by Submarket By Drug Forecast 2020-2030 ($ million)
Figure 4.20 Global Attention Deficit Hyperactivity Disorder Market, by Share Forecast 2019, 2025, 2029 (% Share)
Figure 4.21 Attention Deficit Hyperactivity Disorder Market, By Drug Type Forecast 2020-2030 ($billion, AGR%)
Figure 4.23 Attention Deficit Hyperactivity Disorder Market, By Distribution Channel System Forecast 2020-2030 ($billion, AGR%)
Figure 4.25 Attention Deficit Hyperactivity Disorder Market, By Drug Forecast 2020-2030 ($billion, AGR%)
Figure 4.27 Attention Deficit Hyperactivity Disorder Market, By Drug Type Forecast 2020-2030 ($billion, AGR%)
Figure 5.1 Regional/Country Attention Deficit Hyperactivity Disorder Market, by 2020-2030
Figure 5.3 Leading Country/Regional Attention Deficit Hyperactivity Disorder Market Share, by 2020
Figure 5.4 Leading Country/Regional Attention Deficit Hyperactivity Disorder Market Share, by 2025
Figure 5.5 Leading Country/Regional Attention Deficit Hyperactivity Disorder Market Share, by 2030
Figure 5.6 Europe Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.7 Europe Attention Deficit Hyperactivity Disorder Market, by Forecast 2020-2030
Figure 5.8 Europe Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
Figure 5.9 Europe Attention Deficit Hyperactivity Disorder Submarket , By Drug Type Forecast 2020-2030
Figure 5.10 Europe Attention Deficit Hyperactivity Disorder Submarket , By Country Forecast 2020-2030
Figure 5.11 Europe Attention Deficit Hyperactivity Disorder Submarket , By Distribution Channel 2020-2030 ($billion, AGR%)
Figure 5.10 North America Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.11 North America Attention Deficit Hyperactivity Disorder Market, by Forecast 2020-2030
Figure 5.12 North America Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
Figure 5.13 North America Attention Deficit Hyperactivity Disorder Submarket , By Drug Type Forecast 2020-2030
Figure 5.14 North America Attention Deficit Hyperactivity Disorder Submarket , By Distribution Channel Forecast 2020-2030
Figure 5.13 North America Attention Deficit Hyperactivity Disorder Submarket , By Country Forecast 2020-2030
Figure 5.14 Asia-Pacific Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($billion , AGR%)
Figure 5.15 Asia-Pacific Attention Deficit Hyperactivity Disorder Market, by Forecast 2020-2030
Figure 5.16 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
Figure 5.17 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket , By Country Forecast 2020-2030
Figure 5.17 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket , By Distribution Channel Forecast 2020-2030
Figure 5.18 Rest of World Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($billion, AGR%)
Figure 5.19 Rest of World Attention Deficit Hyperactivity Disorder Market, by Forecast 2020-2030
Figure 5.20 Rest of World Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030
Figure 5.21 Rest of World Attention Deficit Hyperactivity Disorder Submarket , By Drug Type Forecast 2020-2030
Figure 5.21 Rest of World Attention Deficit Hyperactivity Disorder Submarket , By Distribution Channel Forecast 2020-2030
Figure 6.1 3M Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.2 Eli Lily & Company Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.3 GI Dynamics Total Company Sales 2013-2019 (US$ Bn, AGR %)
Figure 6.6 NEOS Therapeutics Inc. Company Sales 2013-2019 (US$ bn, AGR %)
Figure 6.7 NEOS Therapeutics Inc. Revenue % Share, by Distribution Channel Segment, 2019
Figure 6.8 NEOS Therapeutics Inc. Revenue % Share, by Geographical Trade, 2019
Figure 6.9 NEOS Therapeutics Inc. Revenue % Share, by Business Segment, 2019
Figure 6.10 Prude Pharma L.P. Revenue % Share, by Geographic Segment, 2019
Figure 6.11 Mallinckrodt Company Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.12 Shire Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.13 Shire Revenue % Share, by Regional Segment, 2019
Figure 6.14 Lupin Total Company Sales 2013-2019 (US$ million, AGR %)
Figure 6.15 Lupin Revenue % Share, by Regional Segment, 2019
Figure 6.16 Lupin Revenue % Share, by Business Segment, 2019
Figure 6.17 Johnson & Johnson Services, LLC Total Company Sales 2013-2019 (US$ bn, AGR %)
Figure 6.18 Pfizer Total Company Revenue 2013-2019 (US$ bn, AGR %)
Figure 6.19 Pfizer Company Sales 2014-2019 (US$ bn, AGR %)
Figure 6.20 Pfizer Revenue % Share, by Business Segment, 2019
List of Tables
Table 1.0 Research Scope
Table 4.1 Global Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($Bn, AGR %, CAGR %)
Table 4.2 Global Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030 ($billion, AGR %)
Table 4.3 Global Attention Deficit Hyperactivity Disorder Submarket, By Distribution Channel Forecast 2020-2030 ($billion, AGR %)
Table 5.1 Global Attention Deficit Hyperactivity Disorder Market, by Country/Region Forecast 2020-2030 ($billion, AGR %)
Table 5.3 Europe Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.4 Europe Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030 ($billion, AGR %)
Table 5.5 Europe Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)
Table 5.6 North America Attention Deficit Hyperactivity Disorder Market Submarket, By Distribution Channel Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.7 North America Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030 ($billion, AGR %)
Table 5.8 North America Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)
Table 5.9 Asia-Pacific Attention Deficit Hyperactivity Disorder Market Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.10 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030 ($billion, AGR %)
Table 5.11 Asia-Pacific Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)
Table 5.12 Rest of World Attention Deficit Hyperactivity Disorder Market Submarket, By Distribution Channel Forecast 2020-2030 ($billion, , AGR %, CAGR %)
Table 5.13 Rest of World Attention Deficit Hyperactivity Disorder Submarket, By Drug Forecast 2020-2030 ($billion, AGR %)
Table 5.14 Rest of World Attention Deficit Hyperactivity Disorder Submarket, By Drug Type Forecast 2020-2030 ($billion, AGR %)
Table 6.1 3M Profile 2019 (Market Entry, Public/Private, Headquarters, Geography, Key Market, Listed on, Products/Services
Table 6.2 3M Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.3 3M Products and Services (Product/Service, Segment)
Table 6.4 3M Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.5 3M Total Company Recent Development 2015-2019
Table 6.6 Eli Lily & Company Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.7 Eli Lily & Company Products and Services (Product/Service, Segment)
Table 6.8 Eli Lily & Company Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.9 Eli Lily & Company Total Company Recent Development 2015-2019
Table 6.10 GI Dynamics Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.11 GI Dynamics Products and Services (Product/Service, Segment)
Table 6.12 GI Dynamics Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.13 GI Dynamics Total Company Recent Development 2015-2019
Table 6.14 NEOS Therapeutics Inc. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.15 NEOS Therapeutics Inc. Products and Services (Product/Service, Segment)
Table 6.16 NEOS Therapeutics Inc. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.17 NEOS Therapeutics Inc. Total Company Recent Development 2015-2019
Table 6.18 Prude Pharma L.P. Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.19 Prude Pharma L.P. Products and Services (Product/Service, Segment)
Table 6.20 Prude Pharma L.P. Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.21 Prude Pharma L.P. Total Company Recent Development 2015-2019
Table 6.22 Mallinckrodt Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.23 Mallinckrodt Products and Services (Product/Service, Segment)
Table 6.24 Mallinckrodt Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.25 Mallinckrodt Total Company Recent Development 2015-2019
Table 6.26 Shire Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.27 Shire Products and Services (Product/Service, Segment)
Table 6.28 Shire Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.29 Shire Total Company Recent Development 2015-2019
Table 6.30 Lupin Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.31 Lupin Products and Services (Product/Service, Segment)
Table 6.32 Lupin Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.33 Lupin Total Company Recent Development 2015-2019
Table 6.34 Johnson & Johnson Services, LLC Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.35 Johnson & Johnson Services, LLC Products and Services (Product/Service, Segment)
Table 6.36 Johnson & Johnson Services, LLC Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.37 Johnson & Johnson Services, LLC Total Company Recent Development 2015-2019
Table 6.38 Pfizer Profile 2019 (CEO, Total Company Sales US$m, Sales in the Market US$m, Share of Company Sales from MHealth Market %, Net Income / Loss US$m, Strongest Business Region, Business Segment in the Market, Submarket Involvement, HQ, Founded, No. of Employees, Website)
Table 6.39 Pfizer Products and Services (Product/Service, Segment)
Table 6.40 Pfizer Total Company Sales 2015-2019 (US$billion, AGR %)
Table 6.41 Pfizer Total Company Recent Development 2015-2019
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
